Increased investment brings total up to $400 million.

Amylin is increasing construction at the manufacturing facility in West Chester, OH, to increase investment to a total of approximately $400 million.

The company is expanding its existing production plant near the Union Center Boulevard district, which is now in the process of being equipped to manufacture it long-acting release (LAR) formulation of exenatide, a compound in development for type 2 diabetes.

Previous articleHSV-1 Silences Genes to Hide from Immune System
Next articlePhyton Acquires Glyco-Engineering Technique